Elicio Reports Complete Responses in Pancreatic Cancer Patients Receiving ELI-002 7P Plus Checkpoint Inhibition

Elicio Therapeutics reported that three metastatic pancreatic cancer patients achieved confirmed complete responses after receiving ELI-002 7P followed by nivolumab-based therapy, with responses persisting 8+ months. The company plans to initiate a Phase 1 study combining ELI-002 7P with checkpoint inhibitors in first-line metastatic pancreatic cancer, potentially enabling a rapid development pathway if validated.